Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo.
Curr Eye Res
; 39(9): 859-70, 2014 Sep.
Article
en En
| MEDLINE
| ID: mdl-24559478
Currently, the most effective outflow drugs approved for clinical use are prostaglandin F2α analogues, but these require daily topical self-dosing and have various intraocular, ocular surface and extraocular side effects. Lentiviral vector-mediated delivery of the prostaglandin F synthase (PGFS) gene, resulting in long-term reduction of intraocular pressure (IOP), may eliminate off-target tissue effects and the need for daily topical PGF2α self-administration. Lentiviral vector-mediated delivery of the PGFS gene to the anterior segment has been achieved in cats and non-human primates. Although these results are encouraging, our studies have identified a number of challenges that need to be overcome for prostaglandin gene therapy to be translated into the clinic. Using examples from our work in non-human primates, where we were able to achieve a significant reduction in IOP (2 mm Hg) for 5 months after delivery of the cDNA for bovine PGF synthase, we identify and discuss these issues and consider several possible solutions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hidroxiprostaglandina Deshidrogenasas
/
Técnicas de Transferencia de Gen
/
Lentivirus
/
Vectores Genéticos
Límite:
Animals
Idioma:
En
Revista:
Curr Eye Res
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Reino Unido